Quanterix Corporation (QTRX)
NASDAQ: QTRX · Real-Time Price · USD
5.73
+0.45 (8.52%)
At close: May 12, 2025, 4:00 PM
5.61
-0.12 (-2.09%)
After-hours: May 12, 2025, 5:37 PM EDT
Quanterix Revenue
Quanterix had revenue of $30.33M in the quarter ending March 31, 2025, a decrease of -5.40%. This brings the company's revenue in the last twelve months to $135.69M, up 7.71% year-over-year. In the year 2024, Quanterix had annual revenue of $137.42M with 12.30% growth.
Revenue (ttm)
$135.69M
Revenue Growth
+7.71%
P/S Ratio
1.60
Revenue / Employee
$288,085
Employees
471
Market Cap
222.19M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 137.42M | 15.05M | 12.30% |
Dec 31, 2023 | 122.37M | 16.85M | 15.96% |
Dec 31, 2022 | 105.52M | -5.03M | -4.55% |
Dec 31, 2021 | 110.56M | 24.18M | 27.99% |
Dec 31, 2020 | 86.38M | 29.64M | 52.25% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
QTRX News
- 3 hours ago - Quanterix Releases Financial Results for the First Quarter of 2025 - Business Wire
- 5 days ago - AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA - Business Wire
- 7 days ago - Quanterix To Report First Quarter 2025 Financial Results on May 12, 2025 - Business Wire
- 12 days ago - Kent Lake Issues Statement on Quanterix's Blatant Disregard for Will of Shareholders - Business Wire
- 13 days ago - Quanterix and Akoya Biosciences Announce Amended Merger Agreement - Business Wire
- 25 days ago - Kent Lake Files Definitive Proxy Statement and Sends Letter to Quanterix Shareholders - Business Wire
- 4 weeks ago - Tikvah Management Calls on Quanterix to Explain the Egregious Terms of Convertible Notes Purchased from Akoya Biosciences - Business Wire
- 5 weeks ago - Kent Lake Comments on Quanterix's Value Destructive Bridge Financing for Financially Troubled Akoya - Business Wire